<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703482</url>
  </required_header>
  <id_info>
    <org_study_id>CFEN0205</org_study_id>
    <nct_id>NCT00703482</nct_id>
  </id_info>
  <brief_title>A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to study the effect of different combinations of fenofibrate
      and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the E'/E septal ratio</measure>
    <time_frame>End of study (V6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of the LVDD</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the Left atrium and right atrium volumes</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the Left and right sizes</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the LVEDD and LVESD</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the LVEDV and LVESV</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the LV mass</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the LV ejection fraction</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the IVRT</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the tissue Doppler E'/A' ratio</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the PV doppler parameters</measure>
    <time_frame>End of study (V6)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Patients With Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate pbo/CoQ10 placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate pbo/CoQ10 200 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate 160mg/CoQ10 placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate 80/CoQ10 100 mg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate 160mg/CoQ10 100 mg</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate 80 /CoQ10 200 mg</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate/CoQ10</intervention_name>
    <description>Fenofibrate 160mg/CoQ10 200 mg</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged from 40 to 79 years

          -  Patients with pre-existing T2DM

          -  HbA1C &lt;9%

          -  Written informed consent

        Exclusion Criteria:

          -  unable to comply with the protocol, Likely to leave the trial before completion

          -  having participated in an another trial 3Ã  days before V1

          -  Pregnant or childbearing potential not using birth control method

          -  Type 1 diabetic patients, T2Dm insulin therapy

        Patients with one of the following pathology:

          -  with muscular disorders known or increase CK , or hepatic deficiency or transaminase
             increase

          -  with symptomatic gall-bladder disease or/and renal insufficiency

          -  with abnormal thyroid function

          -  with proliferative retinopathy

          -  with recent cardiovascular event, uncontrolled hypertension

          -  with known chronic alcohol intake

          -  with other severe pathology

          -  with TC&gt;= 7.0 mmol/L and/or TG&gt;= 4mmol/L at V1

          -  Patients treated with Warfarin

          -  Patients with specific ECG dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 002</name>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 003</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 001</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>June 24, 2008</last_update_submitted>
  <last_update_submitted_qc>June 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jean Claude Ansquer</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Ventricular diastolic Function</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

